A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Durvalumab (Primary) ; Microbiome modulators (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 Dec 2022 Status changed from not yet recruiting to recruiting.
- 02 Nov 2022 Planned initiation date changed from 1 Jun 2022 to 1 Nov 2022.
- 04 Apr 2022 Planned initiation date changed from 1 Feb 2022 to 1 Jun 2022.